Multiple Myeloma Clinical Trial
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Summary
The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.
Eligibility Criteria
Inclusion Criteria:
Participant has a history of RRMM, and must:
Part A: Have previously received ≥ 3 prior lines of anti-myeloma therapy.
Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.
Exclusion Criteria:
• Must not have previously received alnuctamab or mezigdomide.
Note: Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Birmingham Alabama, 35294, United States
New Haven Connecticut, 06511, United States
New York New York, 10065, United States
Petah-Tikva HaMerkaz, 49100, Israel
Ramat Gan HaMerkaz, 52621, Israel
Jerusalem , 91120, Israel
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.